32 min

Diagnosing Skin Cancer; Theranostics; a Phase 3 Trial with abrocitinib in Atopic Dermatitis and a Link Between Sugary Drinks and CRC Physician's Weekly

    • Medicine

One in five Americans is expected to develop skin cancer by the age of 70. With over 5 million cases diagnosed in the United States each year, skin cancer is America’s most common cancer. Fortunately, skin cancer is also one of the most preventable forms of cancer. Early detection is vital for the successful treatment of skin cancers. When detected early, it is possible to treat skin cancer when it’s easiest to cure before it becomes dangerous, disfiguring, or deadly. So… what if you can diagnose skin cancer with a cell phone? Paul Schmidt asked Vlado Bosanac, Chief Executive Officer of Advanced Human Imaging about using cell phones in diagnosing skin cancer.

Also in this episode of Physician’s Weekly:

- Peter Hofland, Ph.D. speaks with Gill Padula, MD, Chief Medical Officer at University Hospitals St. John Medical Center, near Cleveland and a Clinical Collaborator for NuView Lifesciences, a company preparing to expand its portfolio for Theranostics applications using the NV-VPAC1™ peptide analog by pairing a diagnostic imaging positron emitter, Copper- 64 (Cu-64), with a beta-emitter, Copper-67 (Cu-67), about the Theranostics approach and how it allows physicians to diagnose and localize cancer, and subsequently visualize where the therapy is delivered, and enhance monitoring response to therapy.

- Rachel Giles, MD, asked Ricardo Rojo Cella, MD, Executive Director at Pfizer about the results of a Phase 3 study investigating abrocitinib, an investigational oral JAK1 inhibitor, in patients 12 and older with moderate to severe atopic dermatitis

And finally, this edition of Physician’s Weekly concludes with a report about a study led by Washington University School of Medicine in St. Louis which has found a link between consuming sugary drinks and an increased risk of colorectal cancer among women under 50. The findings suggest that heavy consumption of sugary drinks between the ages of 13 and 18 and adulthood can increase the risk of disease. In the study, which was published online on May 6, 2021, in the journal Gut, the authors provide more support for public health efforts that encourage people to reduce the amount of sugar they consume.

Reference
[1] Hur J, Otegbeye E, Joh HK, Nimptsch K, Ng K, Ogino S, Meyerhardt JA, Chan AT, Willett WC, Wu K, Giovannucci E, Cao Y. Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women. Gut. 2021 May 6:gutjnl-2020-323450. doi: 10.1136/gutjnl-2020-323450. Epub ahead of print. PMID: 33958435.
[2] Garcia D. Study Finds Link Between Consuming Sugary Drinks and an Increased Risk of Colorectal Cancer. Onco’Zine, May 6, 2021 https://tinyurl.com/gutsugarcrc

One in five Americans is expected to develop skin cancer by the age of 70. With over 5 million cases diagnosed in the United States each year, skin cancer is America’s most common cancer. Fortunately, skin cancer is also one of the most preventable forms of cancer. Early detection is vital for the successful treatment of skin cancers. When detected early, it is possible to treat skin cancer when it’s easiest to cure before it becomes dangerous, disfiguring, or deadly. So… what if you can diagnose skin cancer with a cell phone? Paul Schmidt asked Vlado Bosanac, Chief Executive Officer of Advanced Human Imaging about using cell phones in diagnosing skin cancer.

Also in this episode of Physician’s Weekly:

- Peter Hofland, Ph.D. speaks with Gill Padula, MD, Chief Medical Officer at University Hospitals St. John Medical Center, near Cleveland and a Clinical Collaborator for NuView Lifesciences, a company preparing to expand its portfolio for Theranostics applications using the NV-VPAC1™ peptide analog by pairing a diagnostic imaging positron emitter, Copper- 64 (Cu-64), with a beta-emitter, Copper-67 (Cu-67), about the Theranostics approach and how it allows physicians to diagnose and localize cancer, and subsequently visualize where the therapy is delivered, and enhance monitoring response to therapy.

- Rachel Giles, MD, asked Ricardo Rojo Cella, MD, Executive Director at Pfizer about the results of a Phase 3 study investigating abrocitinib, an investigational oral JAK1 inhibitor, in patients 12 and older with moderate to severe atopic dermatitis

And finally, this edition of Physician’s Weekly concludes with a report about a study led by Washington University School of Medicine in St. Louis which has found a link between consuming sugary drinks and an increased risk of colorectal cancer among women under 50. The findings suggest that heavy consumption of sugary drinks between the ages of 13 and 18 and adulthood can increase the risk of disease. In the study, which was published online on May 6, 2021, in the journal Gut, the authors provide more support for public health efforts that encourage people to reduce the amount of sugar they consume.

Reference
[1] Hur J, Otegbeye E, Joh HK, Nimptsch K, Ng K, Ogino S, Meyerhardt JA, Chan AT, Willett WC, Wu K, Giovannucci E, Cao Y. Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women. Gut. 2021 May 6:gutjnl-2020-323450. doi: 10.1136/gutjnl-2020-323450. Epub ahead of print. PMID: 33958435.
[2] Garcia D. Study Finds Link Between Consuming Sugary Drinks and an Increased Risk of Colorectal Cancer. Onco’Zine, May 6, 2021 https://tinyurl.com/gutsugarcrc

32 min